Bioequivalence Analysis of 2 Dapoxetine Hydrochloride Formulations in Healthy Chinese Male Volunteers Under Fed and Fasting Conditions : A Randomized, Open-Label, 2-Sequence, 2-Period, 2-Way Crossover Study
© 2021, The American College of Clinical Pharmacology..
This study assessed whether the reference and test formulations of dapoxetine hydrochloride were bioequivalent under fed and fasting conditions postadministration of a single dose as well as evaluated the safety profile of these 2 formulations. This study was a randomized, single-center, 2-period, open-label, 2-way crossover design study with a washout period of 7 days between each period. The study included 80 subjects, 40 under fed and 40 under fasting conditions. During each study period, the subjects were administered a single oral dose of either the reference or the test formulation, followed by collection of plasma samples 70 hours postdose. High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) was performed to determine the concentrations of dapoxetine in plasma samples along with the calculation of Cmax , AUC0-t, and AUC0-inf . In addition, adverse events were monitored to determine the safety of these formulations. The geometric mean ratio (90%CI) for the reference and test formulations was 86% to 100%, 89% to 103%, and 89% to 103% under fasting conditions and 92% to 107%, 91% to 100%, and 92% to 101% under fed conditions for Cmax , AUC0-t , and AUC0-inf , respectively. The 90%CIs for the test/reference ratio for AUC and Cmax were within the acceptable limits of bioequivalence, thus demonstrating bioequivalence for these 2 dapoxetine hydrochloride formulations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Clinical pharmacology in drug development - 10(2021), 4 vom: 01. Apr., Seite 384-392 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yan, Keyu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.03.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cpdd.866 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319493504 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319493504 | ||
| 003 | DE-627 | ||
| 005 | 20231225171547.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cpdd.866 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM319493504 | ||
| 035 | |a (NLM)33385318 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yan, Keyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bioequivalence Analysis of 2 Dapoxetine Hydrochloride Formulations in Healthy Chinese Male Volunteers Under Fed and Fasting Conditions |b A Randomized, Open-Label, 2-Sequence, 2-Period, 2-Way Crossover Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021, The American College of Clinical Pharmacology. | ||
| 520 | |a This study assessed whether the reference and test formulations of dapoxetine hydrochloride were bioequivalent under fed and fasting conditions postadministration of a single dose as well as evaluated the safety profile of these 2 formulations. This study was a randomized, single-center, 2-period, open-label, 2-way crossover design study with a washout period of 7 days between each period. The study included 80 subjects, 40 under fed and 40 under fasting conditions. During each study period, the subjects were administered a single oral dose of either the reference or the test formulation, followed by collection of plasma samples 70 hours postdose. High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) was performed to determine the concentrations of dapoxetine in plasma samples along with the calculation of Cmax , AUC0-t, and AUC0-inf . In addition, adverse events were monitored to determine the safety of these formulations. The geometric mean ratio (90%CI) for the reference and test formulations was 86% to 100%, 89% to 103%, and 89% to 103% under fasting conditions and 92% to 107%, 91% to 100%, and 92% to 101% under fed conditions for Cmax , AUC0-t , and AUC0-inf , respectively. The 90%CIs for the test/reference ratio for AUC and Cmax were within the acceptable limits of bioequivalence, thus demonstrating bioequivalence for these 2 dapoxetine hydrochloride formulations | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HPLC-MS/MS | |
| 650 | 4 | |a bioequivalence | |
| 650 | 4 | |a dapoxetine hydrochloride | |
| 650 | 4 | |a food effect | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 7 | |a Benzylamines |2 NLM | |
| 650 | 7 | |a Naphthalenes |2 NLM | |
| 650 | 7 | |a Serotonin Uptake Inhibitors |2 NLM | |
| 650 | 7 | |a dapoxetine |2 NLM | |
| 650 | 7 | |a GB2433A4M3 |2 NLM | |
| 700 | 1 | |a Ju, Gehang |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Qiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Lijiao |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Wen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology in drug development |d 2012 |g 10(2021), 4 vom: 01. Apr., Seite 384-392 |w (DE-627)NLM250185032 |x 2160-7648 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:4 |g day:01 |g month:04 |g pages:384-392 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cpdd.866 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 4 |b 01 |c 04 |h 384-392 | ||